NASDAQ
15.05.25 | 15:39
14,260 US-Dollar
+0,49 % +0,070
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | LENSAR, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | LENSAR, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | LENSAR, Inc.: LENSAR Reports First Quarter 2025 Results and Provides Business Update | 47 | GlobeNewswire (Europe) | 14 ALLY Robotic Laser Cataract Systems ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first... ► Artikel lesen | |
| 25.03. | ALC Stock Rises Following the Merger Agreement With LENSAR | 1 | Zacks | ||
| 24.03. | BTIG cuts LENSAR stock rating post Alcon acquisition deal | 5 | Investing.com | ||
| 24.03. | M&A Snapshot: Alcon to acquire LENSAR to boost its cataract equipment portfolio | 6 | Seeking Alpha | ||
| LENSAR Aktie jetzt für 0€ handeln | |||||
| 24.03. | Alcon agrees to acquire Lensar and its robotic cataract laser system | 3 | MassDevice | ||
| 24.03. | Alcon erweitert Portfolio durch Übernahme von Lensar | 10 | IT BOLTWISE | ||
| 24.03. | Alcon Agrees To Acquire LENSAR For Up To Approximately $430 Mln | 431 | AFX News | WASHINGTON (dpa-AFX) - Eye care company Alcon, Inc. (ALC) and medical technology company LENSAR, Inc. (LNSR) announced Monday the companies have entered into a definitive merger agreement through... ► Artikel lesen | |
| 24.03. | Alcon übernimmt Medtech-Unternehmen Lensar für bis zu 430 Millionen Dollar | 499 | Moneycab | Genf - Der Augenheilkundespezialist Alcon kauft in den USA zu. Für bis zu 430 Millionen Dollar übernimmt das Genfer Unternehmen das Medizintechnikunternehmen Lensar aus den USA. Lensar ist laut einer... ► Artikel lesen | |
| 24.03. | Alcon agrees to acquire LENSAR for $14.00 per share | 6 | Seeking Alpha | ||
| 24.03. | Alcon übernimmt LENSAR für bis zu 430 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 24.03. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Alcon Agrees to Acquire LENSAR, Inc. | 337 | Business Wire | Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency... ► Artikel lesen | |
| 06.03. | LENSAR - Top Healthcare Equipment Stock | 4 | Barchart.com | ||
| 04.03. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 105 | GlobeNewswire (Europe) | ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors... ► Artikel lesen | |
| 28.02. | LENSAR, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 10 | SEC Filings | ||
| 27.02. | LENSAR, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.02. | LENSAR, Inc.: LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update | 160 | GlobeNewswire (Europe) | 31 ALLY Robotic Cataract Laser Systems placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately... ► Artikel lesen | |
| 27.02. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 61,85 | -0,08 % | Ihre wichtigsten Termine: Alle Blicke auf: Boeing, Bayer, Carl Zeiss Meditec, Rheinmetall, Sixt & Jenoptik | © Foto: Bayer AGGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| ROKU | 61,96 | -3,71 % | It's Possible to Set Up a VPN on Roku, But You'll Need to Follow These Steps | ||
| HIMS & HERS HEALTH | 50,80 | -7,23 % | Hims & Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month | ||
| MEDICLIN | 3,000 | +0,67 % | MEDICLIN: Eine überraschende Bilanz | MEDICLIN (DE0006595101) meldete ein erfolgreiches erstes Quartal 2025 mit einer deutlichen Steigerung des Betriebsergebnisses auf 5,2 Millionen Euro. Während der Konzernumsatz mit 184,8 Millionen Euro... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| EMEIS | 10,420 | -3,96 % | emeis: Sales and business to end-March 20251 | Further rise in occupancy rates in France and abroad Occupancy rates growth, particularly in nursing homes (France, Northern Europe, Central Europe) Organic sales growth of +6.2%2, Occupancy... ► Artikel lesen | |
| VERU | 0,446 | -1,28 % | JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level | Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| LIFEWARD | 1,340 | -6,94 % | Lifeward Ltd. Reports First Quarter 2025 Financial Results | U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved... ► Artikel lesen | |
| SENSEONICS | 0,513 | +0,04 % | Senseonics targets $34M-$38M revenue in 2025 with Eversense 365 expansion | ||
| CLOVER HEALTH INVESTMENTS | 2,880 | -3,00 % | CLOVER HEALTH INVESTMENTS, CORP. /DE - 8-K, Current Report | ||
| SURGICAL SCIENCE SWEDEN | 13,510 | -2,38 % | Surgical Science Sweden AB: Interim report January - March 2025: Strong growth despite macroeconomic uncertainties | First quarter 2025 (Jan-Mar)
Net sales amounted to SEK 250.7 (188.2) million, an increase of 33 percent compared with the corresponding period in the preceding year. SEK 18.3 million was acquired revenue.License... ► Artikel lesen | |
| BONESUPPORT | 26,060 | +0,62 % | Bonesupport Holding AB: Upcoming CEO change. Emil Billbäck will transfer to a role as Senior Advisor. Torbjörn Sköld will start as CEO effective September 1st, 2025 | BONESUPPORT, a leading company in orthobiologics for the management of bone injuries, today announces the coming transition of leadership at Bonesupport.
Lennart Johansson states: Emil Billbäck will... ► Artikel lesen | |
| EKSO BIONICS | 0,428 | +7,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Accepted into NVIDIA Connect Program | ||
| UNITEDHEALTH | 228,60 | -17,11 % | UnitedHealth Group-Aktie leicht im Minus (338,6583 €) | Im US-amerikanischen Wertpapierhandel liegt die Aktie der UnitedHealth Group gegenwärtig im Minus. Die Aktie notiert derzeit bei 381,59 US-Dollar. Die UnitedHealth Group-Aktie verzeichnet aktuell ein... ► Artikel lesen |
LENSAR INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,070 (+0,49 %) liegt der Kurs bei 14,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LENSAR INC finden Sie auf Wallstreet Online.